Clinical Evidence

THE FOLLOWING WILL DETAIL PAST AND FUTURE CLINICAL EVIDENCE 

 

REDUCING EXTRALUMINAL SKIN FLORA ATTACHMENT DURING PIV INSERTION USING THROUGH-THE-NEEDLE INSERTION METHODS

In association with the North American Science Associates (NAMSA), SkyDance demonstrated a 66% reduction in catheter colonization when through-the-needle catheter deployment was compared to the traditional over-the needle configuration in a benchtop scientific study. These results were presented at the Association of Vascular Access 2019 Annual Scientific Meeting, where it was awarded a People’s Choice Award. The full report is available for download.

CLINICAL USABILITY FOCUS GROUP

In October of 2020, a clinical usability focus group will be held to elicit user feedback of the Osprey version 2 PIV in a simulated use environment.

RANDOMIZED CLINICAL TRIALS

ANIMAL - In Q4, 2020, a randomized controlled study will be initiated to evaluate colonization rates between the Osprey PIV and traditional PIVs in an animal model.  Study results to be available immediatly upon the completion of the study with publication planned.

HUMAN - Human randomized control study protocol drafts are complete. These will examine insertion success and outcomes related comparative data. They are intended to begin in the second quarter of 2021 with a conclusion in the fourth quarter of that year.

logo

Contact Us

1104 Nassau Street
Suite 107
Delray Beach, FL 33483

630 Komas Drive
Suite 204
Salt Lake City, UT  84108

Phone: 754.600.1298

www.skydancevascular.com

Osprey reversed